Only 16% of the patients were using biologic agents, represented by rituximab in AAV patients and by tumor necrosis factor alpha (TNFα) antagonists for UC therapy. This evidence concerns the gene TNF and anti-neutrophil cytoplasmic antibody-associated vasculitis.